Child screening for cholesterol to find FH
A story featuring HEART UK's call to screen children at an early age along with the McKenzie family from Cornwall was a major feature in the Mail on Sunday on 6th October 2019. Read the full story here.
A story featuring HEART UK's call to screen children at an early age along with the McKenzie family from Cornwall was a major feature in the Mail on Sunday on 6th October 2019. Read the full story here.
Recently non-HDL cholesterol has been recommended to replace LDL cholesterol in the clinical management of dyslipidaemia routinely in general medical practice. The authors claim this is misguided.
Research suggests adherence to lifelong pharmacological and lifestyle treatment by people with FH is poor. This study explores the qualitative research to identify enablers and barriers to treatment adherence.
To describe demographic characteristics, current local clinical management and outcomes for patients with familial hypercholesterolaemia (FH) managed at the Royal Brompton and Harefield NHS Foundation Trust (RBHT), a specialist UK tertiary cardiac centre.
Source: Journal of Clinical Lipidology and Metabolic Disorders
Familial chylomicronemia syndrome is a rare genetic disorder that is caused by loss of lipoprotein lipase activity and characterized by chylomicronemia and recurrent episodes of pancreatitis. There are no effective therapies. In an open-label study of three patients with this syndrome, antisense-mediated inhibition of hepatic APOC3 mRNA with volanesorsen led to decreased plasma apolipoprotein C-III and triglyceride levels.
Different lines of investigation suggest that “dietary quality” rather than “nutrient quantity” is a more reliable index for healthy nutrition. Any meaningful dietary intervention ought to extend far beyond the current focus on nutrient quantity and include the myriad qualitative aspects of food and food combinations, which would affect health and disease states.
Source:The Journal of Clinical Investigation
An appraisal of currently available and emerging therapies for lowering LDL cholesterol, lipoprotein(a), and triglycerides for prevention of ischaemic heart disease.
Source: The Lancet
A consensus statement by HEART UK on a strategy with age appropriate guidance for managing children and young people with heterozygous FH in the UK.